SCHEDULE: FMR LLC Discloses 6.4% Stake in Biogen Inc.

Sentiment:

Beneficial Ownership Report 5 February 2026 1:16 PM

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 6.4% beneficial ownership stake in Biogen Inc. common stock as of December 31, 2025.

Summary

FMR LLC and its affiliates, along with Abigail P. Johnson, beneficially own 9,413,062.03 shares of Biogen Inc. common stock.
This ownership represents 6.4% of Biogen Inc.'s total outstanding common stock.
The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Biogen Inc.
FMR LLC, classified as a parent holding company, reported sole voting power over 8,291,794.64 shares and sole dispositive power over 9,413,062.03 shares.
Abigail P. Johnson, an individual, reported sole dispositive power over 9,413,062.03 shares, reflecting her indirect control through FMR LLC.
Several FMR LLC subsidiaries, including various investment advisers and banks, are listed as entities that beneficially own shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as it confirms a significant, stable institutional ownership by a reputable asset manager, FMR LLC, in Biogen Inc., without any indication of activist intent.

Positives

A significant institutional investor, FMR LLC, maintains a substantial 6.4% stake in Biogen Inc., indicating continued confidence in the company's long-term prospects.

Negatives

Risks

While the filing explicitly states no intent to influence control, a large institutional holding could still exert indirect influence on corporate governance or strategic decisions over time.

Future Outlook

Management Comments

The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, which can influence market perception. FMR LLC, a major asset manager, maintaining a 6.4% position in a biotechnology firm like Biogen Inc. suggests a long-term investment perspective, common among large funds in the healthcare sector known for its innovation and potential for high growth, but also significant R&D costs and regulatory hurdles.

Comparison to Industry Standards

A 6.4% stake by a single institutional investor or affiliated group is a substantial holding, placing FMR LLC among Biogen's top shareholders.
Compared to other large pharmaceutical or biotechnology companies, it is common for institutional investors like BlackRock, Vanguard, or State Street to hold similar or larger passive stakes, often exceeding 5% of outstanding shares.
For example, similar large institutional holdings are observed in companies like Eli Lilly (LLY) or Amgen (AMGN), where major asset managers frequently hold significant passive positions.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Reporting Entity Structure	Abigail P. Johnson, as Director, Chairman, and CEO of FMR LLC, along with other Johnson family members, are predominant owners of FMR LLC's Series B voting common shares, forming a controlling group over FMR LLC.	NA	This clarifies the internal governance structure of the reporting entity, FMR LLC, and its relationship with Abigail P. Johnson, but does not directly impact Biogen Inc.'s corporate governance.

Stakeholder Impact

Shareholders: Provides transparency regarding a major institutional holder's stake, potentially reinforcing confidence due to a stable, long-term investor.
Management: Awareness of a significant passive institutional holder, which typically implies less immediate pressure for operational changes compared to activist investors.

Next Steps

FMR LLC and Abigail P. Johnson will continue to monitor their beneficial ownership in Biogen Inc.
Future Schedule 13G/A amendments will be filed if there are material changes to their ownership stake or investment intent.

Key Dates

Date	Description
January 3, 2023	Effective date of Power of Attorney for FMR LLC.
January 26, 2023	Effective date of Power of Attorney for Abigail P. Johnson.
December 31, 2025	Date of event requiring the filing of this statement, reflecting beneficial ownership as of this date.
February 4, 2026	Date of filing of the Schedule 13G statement.

Recommendation

hold

The filing is a routine disclosure of beneficial ownership by a major institutional investor, FMR LLC, in Biogen Inc. It indicates a stable, passive stake of 6.4% and explicitly states no intent to influence control. This type of filing does not provide new information that would fundamentally alter the investment thesis for Biogen, hence a 'hold' recommendation is appropriate for existing investors, while new investors should base decisions on Biogen's operational performance and market outlook rather than this ownership disclosure.

Keywords

Biogen Inc., BIIB, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.